Analyst Consensus ?
ConsensusHold13 ratings
Bullish538.5%
Neutral753.8%
Bearish17.7%
Viatris Inc. · VTRS · FY2025 Q2 · Calendar Q3 2025
Viatris Maintains Guidance as Pipeline Progress Continues
The quarter supports a constructive but conditional view: operational revenue growth, pipeline progress and maintained guidance provide support, while regulatory execution, facility remediation and tariff exposure remain material constraints.
Reported Before market openNASDAQHealthcare
$20.37B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.62
Consensus $0.56
EPS surprise
+11.5%
Reported versus consensus
Reported revenue
$3.58B
Consensus $3.47B
Revenue surprise
+3.3%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+7.3%
Event window
SPY move
-0.1%
Same window
Abnormal move
+7.4%
Stock minus SPY
Volume
1.8×
Versus trailing sessions
Subsequent drift
+11.8%
Up to 20 sessions
VTRSSPY benchmark
Ask FN2 about VTRS FY2025 Q2
Transcript, numbers and history already loaded
Why did VTRS rise 7.3% after beating EPS estimates in FY2025 Q2?What changed in VTRS's guidance and outlook in FY2025 Q2?Give me the bull and bear case for VTRS after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the bullish score increased from 70 to 78, operational revenue growth was reported at 3% after adjusting for Indore, and management added a planned Q3 strategic-review update while advancing meloxicam and eye-care filings.
Guidance delta
Management reaffirmed 2025 guidance and expects to be in the top half of its revenue and EPS ranges.
Key takeaways
- Operational revenue grew 3% year over year after adjusting for the Indore impact, despite a 2% headline decline.
- Management highlighted positive late-stage data for fast-acting meloxicam and eye-care programs.
- Indore remediation was about 80% complete, with an FDA meeting planned to discuss re-inspection.
- Capital allocation included $350 million of share repurchases and more than $630 million returned year to date.
Management priorities
- Advance regulatory filings and launches for meloxicam, eye-care candidates, EFFEXOR and XULANE.
- Complete Indore remediation and obtain FDA clearance for re-inspection.
- Pursue strategic business-development transactions to build a growth portfolio.
Follow VTRS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$17.49Previous close
$12Low
$18.55Average
$26High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 8, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Oct 5, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Sep 16, 2026 |
| Argus Research | Buy | Buy | Maintain | Sep 8, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 19, 2026 |
| Truist Securities | Buy | Buy | Maintain | May 8, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | May 8, 2026 |
| Jefferies | Buy | Buy | Maintain | Mar 7, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Feb 28, 2025 |
| BMO Capital | Market Perform | Outperform | Downgrade | Feb 17, 2023 |
| Goldman Sachs | Neutral | Neutral | Maintain | May 12, 2022 |
| Citigroup | Neutral | Neutral | Maintain | Mar 10, 2022 |
| Raymond James | Market Perform | Outperform | Downgrade | Mar 1, 2022 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Mar 10, 2021 |
Named analyst price targets
Upside is calculated against the persisted previous close $17.49. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Ashwani Verma | $26 | $17.6 | +48.7% | Oct 5, 2026 |
| Oppenheimer | Analyst unavailable | $25 | $17.18 | +42.9% | Sep 23, 2026 |
| Leerink Partners | Analyst unavailable | $20 | $16.61 | +14.4% | Sep 9, 2026 |
| Argus Research | Analyst unavailable | $20 | $16.75 | +14.4% | Sep 8, 2026 |
| Barclays | Glen Santangelo | $22 | $16.5 | +25.8% | May 19, 2026 |
| Truist Financial | Analyst unavailable | $20 | $16.94 | +14.4% | May 8, 2026 |
| UBS | Ashwani Verma | $18 | $14.58 | +2.9% | Feb 9, 2026 |
| Piper Sandler | Analyst unavailable | $12 | $13.12 | -31.4% | Jan 28, 2026 |
| Argus Research | Analyst unavailable | $15 | $12.84 | -14.2% | Jan 16, 2026 |
| Truist Financial | Les Sulewski | $16 | $12.4 | -8.5% | Jan 7, 2026 |
| Truist Financial | Analyst unavailable | $15 | $9.93 | -14.2% | Oct 15, 2025 |
| Jefferies | Glen Santangelo | $15 | $11.77 | -14.2% | Jul 19, 2024 |
| Piper Sandler | David Amsellem | $13 | $11.83 | -25.7% | Mar 28, 2024 |
| Piper Sandler | David Amsellem | $10 | $9.84 | -42.8% | Jun 26, 2023 |
| Barclays | Analyst unavailable | $15 | $12.16 | -14.2% | Feb 1, 2023 |
| UBS | Ashwani Verma | $12 | $10.83 | -31.4% | Nov 9, 2022 |
| UBS | Ashwani Verma | $9 | $10.77 | -48.5% | Jun 13, 2022 |
Track every rating change on VTRS the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationViatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors.…
Historical context
All VTRS earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
Get the VTRS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-08T06:20:43.132665+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-08T06:20:43.129896+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-08. For educational purposes only; not investment advice.